Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Chairman Sells $61,710.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $7.26, for a total value of $61,710.00. Following the sale, the chairman directly owned 3,387,150 shares in the company, valued at $24,590,709. The trade was a 0.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Monday, October 5th, Jurgi Camblong sold 40,172 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.13, for a total value of $326,598.36.
• On Thursday, September 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.66, for a total value of $65,110.00.
• On Monday, August 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.61, for a total value of $64,685.00.
• On Friday, August 7th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.23, for a total transaction of $144,600.00.
• On Tuesday, August 4th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.92, for a total transaction of $138,400.00.
• On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.63, for a total transaction of $132,600.00.
• On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.29, for a total transaction of $153,356.49.

SOPHiA GENETICS Trading Down 7.7%

SOPH traded down $0.56 during trading on Friday, reaching $6.73. 915,442 shares of the company’s stock were exchanged, compared to its average volume of 625,793. SOPHiA GENETICS SA has a one year low of $3.75 and a one year high of $8.98. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $564.58 million, a PE ratio of -5.85 and a beta of 0.95. The firm has a fifty day moving average price of $7.96 and a two-hundred day moving average price of $6.24.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The business had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. As a group, equities research analysts forecast that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on SOPH. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday. BTIG Research increased their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. HC Wainwright reissued a “buy” rating and issued a $14.00 price target on shares of SOPHiA GENETICS in a research note on Monday, October 12th. Finally, Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $10.00.

Institutional Investors Weigh In On SOPHiA GENETICS

Institutional investors and hedge funds have recently made changes to their positions in the business. First Dallas Securities Inc. acquired a new stake in SOPHiA GENETICS during the first quarter worth approximately $50,000. Royal Bank of Canada increased its holdings in SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after purchasing an additional 18,781 shares in the last quarter. AXQ Capital LP acquired a new position in SOPHiA GENETICS in the second quarter valued at approximately $119,000. Silverberg Bernstein Capital Management LLC lifted its stake in SOPHiA GENETICS by 8.7% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock valued at $257,000 after buying an additional 4,155 shares during the period. Finally, Hennion & Walsh Asset Management Inc. acquired a new position in SOPHiA GENETICS in the second quarter valued at approximately $567,000. Institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.